Sector News

Stryker acquires Arrinex

February 26, 2019
Life sciences

Stryker announced today it has completed the acquisition of Arrinex, Inc., a medical device company headquartered in Menlo Park, California, that has developed ClariFix®, a novel cryoablation technology for the treatment of chronic rhinitis.

This condition, which affects over 24 million people in the U.S. each year, may cause runny nose, congestion, sneezing and nasal itching. Arrinex, which was founded in 2013, began commercializing ClariFix in late 2017 in the U.S. ClariFix further expands Stryker’s Ear, Nose and Throat (ENT) portfolio with a unique product to address a large, underpenetrated segment of the ENT market where Stryker does not currently compete.

“The acquisition of Arrinex is highly complementary to Stryker’s ENT portfolio, which is part of our Neurotechnology business,” said Spencer Stiles, Stryker’s Group President, Neurotechnology, Instruments and Spine. “This acquisition aligns with our focus on providing ENT physicians with new technologies that deliver more treatment options and better patient outcomes.”

Source: Stryker

comments closed

Related News

September 26, 2021

Lonza invests to expand drug product development and manufacturing services in Switzerland

Life sciences

Lonza will invest to expand its drug product manufacturing network in Switzerland. The investment will include installation of a new aseptic fill and finish line in Stein and the expansion of Drug Product Services in Basel. The expansion adds new capabilities to support clinical and commercial manufacturing and enhances existing drug product service offering in Basel and Visp.

September 26, 2021

Repairing heart damage by transiently turning back the clock

Life sciences

Partial reprogramming of adult heart cells to a fetal-like state could help repair heart damage following cardiac injury or disease, scientists at the Max Planck Institute for Heart and Lung Research showed in mice. 

September 26, 2021

Merck women’s health spinoff Organon debuts first awareness campaign, taking on unplanned pregnancy

Life sciences

When Merck’s women’s health spinoff Organon launched in June, it promised to listen to—and amplify—women’s voices on overlooked health concerns. Now, the company is getting specific. Organon hopes to ignite a conversation about an issue that affects 121 million women around the world every year.

Send this to a friend